Chemotherapy fog targets stomach tumors in early trial
NCT ID NCT07487168
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This early-stage trial tests a technique called PIPAC, which turns a chemotherapy drug (mitomycin C) into a mist and sprays it directly onto cancer spread inside the abdomen. It is for people with advanced gastrointestinal cancers that cannot be removed by surgery. The main goal is to find a safe dose and see if it helps control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERITONEAL CARCINOMATOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Mitomycin C (chemotherapy drug)
What this could lead to
If successful, this could offer a new palliative treatment option for patients with advanced abdominal cancer who cannot have standard surgery.
What could go wrong
This is a very early Phase 1 trial with only 24 participants, so safety and the right dose are still unknown. The cancer is advanced and incurable, so the goal is control, not cure.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.